Literature DB >> 20161407

To fold or not to fold: modulation and consequences of Hsp90 inhibition.

Laura B Peterson1, Brian S J Blagg.   

Abstract

BACKGROUND: The 90-kDa heat-shock proteins (Hsp90) have rapidly evolved into promising therapeutic targets for the treatment of several diseases, including cancer and neurodegenerative diseases. Hsp90 is a molecular chaperone that aids in the conformational maturation of nascent polypeptides, as well as the rematuration of denatured proteins. DISCUSSION: Many of the Hsp90-dependent client proteins are associated with cellular growth and survival and, consequently, inhibition of Hsp90 represents a promising approach for the treatment of cancer. Conversely, stimulation of heat-shock protein levels has potential therapeutic applications for the treatment of neurodegenerative diseases that result from misfolded and aggregated proteins.
CONCLUSION: Hsp90 modulation exhibits the potential to treat unrelated disease states, from cancer to neurodegenerative diseases, and, thus, to fold or not to fold, becomes a question of great value.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20161407      PMCID: PMC2784693          DOI: 10.4155/fmc.09.17

Source DB:  PubMed          Journal:  Future Med Chem        ISSN: 1756-8919            Impact factor:   3.808


  168 in total

1.  Clinical and quantitative pathologic correlates of dementia with Lewy bodies.

Authors:  E Gómez-Tortosa; K Newell; M C Irizarry; M Albert; J H Growdon; B T Hyman
Journal:  Neurology       Date:  1999-10-12       Impact factor: 9.910

Review 2.  Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective.

Authors:  Rudolph E Tanzi; Lars Bertram
Journal:  Cell       Date:  2005-02-25       Impact factor: 41.582

Review 3.  Modulation of neurodegeneration by molecular chaperones.

Authors:  Paul J Muchowski; Jennifer L Wacker
Journal:  Nat Rev Neurosci       Date:  2005-01       Impact factor: 34.870

4.  Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin.

Authors:  S M Roe; C Prodromou; R O'Brien; J E Ladbury; P W Piper; L H Pearl
Journal:  J Med Chem       Date:  1999-01-28       Impact factor: 7.446

5.  Identification of autoantibodies associated with myelin damage in multiple sclerosis.

Authors:  C P Genain; B Cannella; S L Hauser; C S Raine
Journal:  Nat Med       Date:  1999-02       Impact factor: 53.440

6.  Regulation of p21(WAF1/CIP1) stability by WISp39, a Hsp90 binding TPR protein.

Authors:  Thomas Jascur; Howard Brickner; Isabelle Salles-Passador; Valerie Barbier; Abdelhamid El Khissiin; Brian Smith; Rati Fotedar; Arun Fotedar
Journal:  Mol Cell       Date:  2005-01-21       Impact factor: 17.970

7.  Identification of CHIP, a novel tetratricopeptide repeat-containing protein that interacts with heat shock proteins and negatively regulates chaperone functions.

Authors:  C A Ballinger; P Connell; Y Wu; Z Hu; L J Thompson; L Y Yin; C Patterson
Journal:  Mol Cell Biol       Date:  1999-06       Impact factor: 4.272

8.  A novel chaperone-activity-reducing mechanism of the 90-kDa molecular chaperone HSP90.

Authors:  H Itoh; M Ogura; A Komatsuda; H Wakui; A B Miura; Y Tashima
Journal:  Biochem J       Date:  1999-11-01       Impact factor: 3.857

9.  Association of NASP with HSP90 in mouse spermatogenic cells: stimulation of ATPase activity and transport of linker histones into nuclei.

Authors:  Oleg M Alekseev; Esther E Widgren; Richard T Richardson; Michael G O'Rand
Journal:  J Biol Chem       Date:  2004-11-08       Impact factor: 5.157

10.  Hsp70 and Hsp40 attenuate formation of spherical and annular polyglutamine oligomers by partitioning monomer.

Authors:  Jennifer L Wacker; M Hadi Zareie; Hanson Fong; Mehmet Sarikaya; Paul J Muchowski
Journal:  Nat Struct Mol Biol       Date:  2004-11-14       Impact factor: 15.369

View more
  47 in total

1.  Synthesis and evaluation of novologues as C-terminal Hsp90 inhibitors with cytoprotective activity against sensory neuron glucotoxicity.

Authors:  Bhaskar Reddy Kusuma; Liang Zhang; Teather Sundstrom; Laura B Peterson; Rick T Dobrowsky; Brian S J Blagg
Journal:  J Med Chem       Date:  2012-06-15       Impact factor: 7.446

2.  Development of a Grp94 inhibitor.

Authors:  Adam S Duerfeldt; Laura B Peterson; Jason C Maynard; Chun Leung Ng; Davide Eletto; Olga Ostrovsky; Heather E Shinogle; David S Moore; Yair Argon; Christopher V Nicchitta; Brian S J Blagg
Journal:  J Am Chem Soc       Date:  2012-05-29       Impact factor: 15.419

3.  Synthesis and structure-activity relationships of EGCG analogues, a recently identified Hsp90 inhibitor.

Authors:  Anuj Khandelwal; Jessica A Hall; Brian S J Blagg
Journal:  J Org Chem       Date:  2013-08-01       Impact factor: 4.354

Review 4.  Anticancer Inhibitors of Hsp90 Function: Beyond the Usual Suspects.

Authors:  Gaurav Garg; Anuj Khandelwal; Brian S J Blagg
Journal:  Adv Cancer Res       Date:  2016-02-10       Impact factor: 6.242

5.  Synthesis and biological evaluation of arylated novobiocin analogs as Hsp90 inhibitors.

Authors:  Bhaskar Reddy Kusuma; Adam S Duerfeldt; Brian S J Blagg
Journal:  Bioorg Med Chem Lett       Date:  2011-10-01       Impact factor: 2.823

6.  Radiosensitizing effect of the novel Hsp90 inhibitor NVP-AUY922 in human tumour cell lines silenced for Hsp90α.

Authors:  L Stingl; N Niewidok; N Müller; M Selle; C S Djuzenova; M Flentje
Journal:  Strahlenther Onkol       Date:  2012-03-24       Impact factor: 3.621

Review 7.  Diabetic peripheral neuropathy: should a chaperone accompany our therapeutic approach?

Authors:  Kevin L Farmer; Chengyuan Li; Rick T Dobrowsky
Journal:  Pharmacol Rev       Date:  2012-08-10       Impact factor: 25.468

8.  Gα12 structural determinants of Hsp90 interaction are necessary for serum response element-mediated transcriptional activation.

Authors:  Ellyn R Montgomery; Brenda R S Temple; Kimberly A Peters; Caitlin E Tolbert; Brandon K Booker; Joseph W Martin; Tyler P Hamilton; Alicia C Tagliatela; William C Smolski; Stephen L Rogers; Alan M Jones; Thomas E Meigs
Journal:  Mol Pharmacol       Date:  2014-01-16       Impact factor: 4.436

9.  Diverging Novobiocin Anti-Cancer Activity from Neuroprotective Activity through Modification of the Amide Tail.

Authors:  Suman Ghosh; Yang Liu; Gaurav Garg; Mercy Anyika; Nolan T McPherson; Jiacheng Ma; Rick T Dobrowsky; Brian S J Blagg
Journal:  ACS Med Chem Lett       Date:  2016-07-05       Impact factor: 4.345

10.  Synthesis and biological evaluation of coumarin replacements of novobiocin as Hsp90 inhibitors.

Authors:  Bhaskar Reddy Kusuma; Anuj Khandelwal; Wen Gu; Douglas Brown; Weiya Liu; George Vielhauer; Jeffrey Holzbeierlein; Brian S J Blagg
Journal:  Bioorg Med Chem       Date:  2014-01-03       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.